Outcomes after reinitiating antiretroviral therapy in children randomized to planned treatment interruptions

Torsak Bunupuradah, Trinh Duong, Alexandra Compagnucci, Paddy McMaster, Stefania Bernardi, Suparat Kanjanavanit, Osvalda Rampon, Albert Faye, Yacine Saïdi, Yoann Riault, Anita De Rossi, Nigel Klein, Jintanat Ananworanich, Diana Gibb

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

BACKGROUND: Excess risks for death/opportunistic disease in adults randomized to CD4-driven planned treatment interruption (PTI) in the Strategies for Management of Antiretroviral Therapy (SMART) trial remained after antiretroviral therapy (ART) re-initiation. Risks for children following PTI were evaluated in long-term follow-up of children in the PENTA 11 trial. METHODS: Children with HIV RNA below 50 copies/ml and CD4 at least 30% (2-6 years) or at least 500 cells/μl (7-15 years) were randomized to continuous ART (cART) or PTI in PENTA 11 (ISRCTN 36694210). After the end of the trial, all were recommended to resume ART. Data were collected annually and analysed up to the second year of visit. RESULTS: One hundred and one (51 cART, 50 PTI; median baseline age 9.2 years) children had median overall follow-up 4.6 (range 3.7-5.0) years. During 2-year post-trial period, there were no deaths or new Centers for Disease Control and Prevention (CDC) stage B/C events. Rate of clinical grade of at least two events was similar between PTI and cART [relative risk (RR) 1.03; 95% confidence interval (CI) 0.43, 2.50; P=0.94]. At 2 years, difference in absolute CD4% between PTI and cART was -1.6% (-4.5%; 1.3%; P=0.27), and proportions with HIV RNA below 50 copies/ml were 82 versus 86% (P=0.57), respectively; no differences in growth or fasting lipids were observed. Key predictors of greater CD4% recovery after re-initiating ART were higher CD4% at baseline (P

Original languageEnglish
Pages (from-to)579-589
Number of pages11
JournalAIDS (London, England)
Volume27
Issue number4
DOIs
Publication statusPublished - Feb 20 2013

Fingerprint

Therapeutics
HIV
RNA
Centers for Disease Control and Prevention (U.S.)
Fasting
Confidence Intervals
Lipids
Growth
PENTA

Keywords

  • antiretroviral therapy
  • ART re-initiation
  • HIV-infected children
  • PTI
  • treatment interruption

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

Outcomes after reinitiating antiretroviral therapy in children randomized to planned treatment interruptions. / Bunupuradah, Torsak; Duong, Trinh; Compagnucci, Alexandra; McMaster, Paddy; Bernardi, Stefania; Kanjanavanit, Suparat; Rampon, Osvalda; Faye, Albert; Saïdi, Yacine; Riault, Yoann; De Rossi, Anita; Klein, Nigel; Ananworanich, Jintanat; Gibb, Diana.

In: AIDS (London, England), Vol. 27, No. 4, 20.02.2013, p. 579-589.

Research output: Contribution to journalArticle

Bunupuradah, T, Duong, T, Compagnucci, A, McMaster, P, Bernardi, S, Kanjanavanit, S, Rampon, O, Faye, A, Saïdi, Y, Riault, Y, De Rossi, A, Klein, N, Ananworanich, J & Gibb, D 2013, 'Outcomes after reinitiating antiretroviral therapy in children randomized to planned treatment interruptions', AIDS (London, England), vol. 27, no. 4, pp. 579-589. https://doi.org/10.1097/QAD.0b013e32835c1181
Bunupuradah, Torsak ; Duong, Trinh ; Compagnucci, Alexandra ; McMaster, Paddy ; Bernardi, Stefania ; Kanjanavanit, Suparat ; Rampon, Osvalda ; Faye, Albert ; Saïdi, Yacine ; Riault, Yoann ; De Rossi, Anita ; Klein, Nigel ; Ananworanich, Jintanat ; Gibb, Diana. / Outcomes after reinitiating antiretroviral therapy in children randomized to planned treatment interruptions. In: AIDS (London, England). 2013 ; Vol. 27, No. 4. pp. 579-589.
@article{aeccaf79c73440ee85169e2c9926a7eb,
title = "Outcomes after reinitiating antiretroviral therapy in children randomized to planned treatment interruptions",
abstract = "BACKGROUND: Excess risks for death/opportunistic disease in adults randomized to CD4-driven planned treatment interruption (PTI) in the Strategies for Management of Antiretroviral Therapy (SMART) trial remained after antiretroviral therapy (ART) re-initiation. Risks for children following PTI were evaluated in long-term follow-up of children in the PENTA 11 trial. METHODS: Children with HIV RNA below 50 copies/ml and CD4 at least 30{\%} (2-6 years) or at least 500 cells/μl (7-15 years) were randomized to continuous ART (cART) or PTI in PENTA 11 (ISRCTN 36694210). After the end of the trial, all were recommended to resume ART. Data were collected annually and analysed up to the second year of visit. RESULTS: One hundred and one (51 cART, 50 PTI; median baseline age 9.2 years) children had median overall follow-up 4.6 (range 3.7-5.0) years. During 2-year post-trial period, there were no deaths or new Centers for Disease Control and Prevention (CDC) stage B/C events. Rate of clinical grade of at least two events was similar between PTI and cART [relative risk (RR) 1.03; 95{\%} confidence interval (CI) 0.43, 2.50; P=0.94]. At 2 years, difference in absolute CD4{\%} between PTI and cART was -1.6{\%} (-4.5{\%}; 1.3{\%}; P=0.27), and proportions with HIV RNA below 50 copies/ml were 82 versus 86{\%} (P=0.57), respectively; no differences in growth or fasting lipids were observed. Key predictors of greater CD4{\%} recovery after re-initiating ART were higher CD4{\%} at baseline (P",
keywords = "antiretroviral therapy, ART re-initiation, HIV-infected children, PTI, treatment interruption",
author = "Torsak Bunupuradah and Trinh Duong and Alexandra Compagnucci and Paddy McMaster and Stefania Bernardi and Suparat Kanjanavanit and Osvalda Rampon and Albert Faye and Yacine Sa{\"i}di and Yoann Riault and {De Rossi}, Anita and Nigel Klein and Jintanat Ananworanich and Diana Gibb",
year = "2013",
month = "2",
day = "20",
doi = "10.1097/QAD.0b013e32835c1181",
language = "English",
volume = "27",
pages = "579--589",
journal = "AIDS",
issn = "0269-9370",
publisher = "NLM (Medline)",
number = "4",

}

TY - JOUR

T1 - Outcomes after reinitiating antiretroviral therapy in children randomized to planned treatment interruptions

AU - Bunupuradah, Torsak

AU - Duong, Trinh

AU - Compagnucci, Alexandra

AU - McMaster, Paddy

AU - Bernardi, Stefania

AU - Kanjanavanit, Suparat

AU - Rampon, Osvalda

AU - Faye, Albert

AU - Saïdi, Yacine

AU - Riault, Yoann

AU - De Rossi, Anita

AU - Klein, Nigel

AU - Ananworanich, Jintanat

AU - Gibb, Diana

PY - 2013/2/20

Y1 - 2013/2/20

N2 - BACKGROUND: Excess risks for death/opportunistic disease in adults randomized to CD4-driven planned treatment interruption (PTI) in the Strategies for Management of Antiretroviral Therapy (SMART) trial remained after antiretroviral therapy (ART) re-initiation. Risks for children following PTI were evaluated in long-term follow-up of children in the PENTA 11 trial. METHODS: Children with HIV RNA below 50 copies/ml and CD4 at least 30% (2-6 years) or at least 500 cells/μl (7-15 years) were randomized to continuous ART (cART) or PTI in PENTA 11 (ISRCTN 36694210). After the end of the trial, all were recommended to resume ART. Data were collected annually and analysed up to the second year of visit. RESULTS: One hundred and one (51 cART, 50 PTI; median baseline age 9.2 years) children had median overall follow-up 4.6 (range 3.7-5.0) years. During 2-year post-trial period, there were no deaths or new Centers for Disease Control and Prevention (CDC) stage B/C events. Rate of clinical grade of at least two events was similar between PTI and cART [relative risk (RR) 1.03; 95% confidence interval (CI) 0.43, 2.50; P=0.94]. At 2 years, difference in absolute CD4% between PTI and cART was -1.6% (-4.5%; 1.3%; P=0.27), and proportions with HIV RNA below 50 copies/ml were 82 versus 86% (P=0.57), respectively; no differences in growth or fasting lipids were observed. Key predictors of greater CD4% recovery after re-initiating ART were higher CD4% at baseline (P

AB - BACKGROUND: Excess risks for death/opportunistic disease in adults randomized to CD4-driven planned treatment interruption (PTI) in the Strategies for Management of Antiretroviral Therapy (SMART) trial remained after antiretroviral therapy (ART) re-initiation. Risks for children following PTI were evaluated in long-term follow-up of children in the PENTA 11 trial. METHODS: Children with HIV RNA below 50 copies/ml and CD4 at least 30% (2-6 years) or at least 500 cells/μl (7-15 years) were randomized to continuous ART (cART) or PTI in PENTA 11 (ISRCTN 36694210). After the end of the trial, all were recommended to resume ART. Data were collected annually and analysed up to the second year of visit. RESULTS: One hundred and one (51 cART, 50 PTI; median baseline age 9.2 years) children had median overall follow-up 4.6 (range 3.7-5.0) years. During 2-year post-trial period, there were no deaths or new Centers for Disease Control and Prevention (CDC) stage B/C events. Rate of clinical grade of at least two events was similar between PTI and cART [relative risk (RR) 1.03; 95% confidence interval (CI) 0.43, 2.50; P=0.94]. At 2 years, difference in absolute CD4% between PTI and cART was -1.6% (-4.5%; 1.3%; P=0.27), and proportions with HIV RNA below 50 copies/ml were 82 versus 86% (P=0.57), respectively; no differences in growth or fasting lipids were observed. Key predictors of greater CD4% recovery after re-initiating ART were higher CD4% at baseline (P

KW - antiretroviral therapy

KW - ART re-initiation

KW - HIV-infected children

KW - PTI

KW - treatment interruption

UR - http://www.scopus.com/inward/record.url?scp=84873408206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873408206&partnerID=8YFLogxK

U2 - 10.1097/QAD.0b013e32835c1181

DO - 10.1097/QAD.0b013e32835c1181

M3 - Article

C2 - 23135172

AN - SCOPUS:84873408206

VL - 27

SP - 579

EP - 589

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 4

ER -